AVALO THERAPEUTICS, INC. (AVTX) Gross margin 2016–2023
AVALO THERAPEUTICS, INC. (AVTX) gross margin by fiscal year — reported gross profit divided by reported revenue.
33.3%FY2023 · since FY2016: 100.0% → 33.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | 33.3% | -47.7 pp |
| FY2022 | 81.0% | +8.6 pp |
| FY2021 | 72.4% | -23.1 pp |
| FY2020 | 95.5% | -12.9 pp |
| FY2019 | 108.4% | +54.8 pp |
| FY2018 | 53.6% | -44.1 pp |
| FY2017 | 97.7% | -2.3 pp |
| FY2016 | 100.0% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross profitAVTX Operating incomeAVTX Operating marginAVTX Operating cash flowAVTX Free cash flowAVTX Capital expendituresAVTX Return on equityAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Total liabilitiesAVTX Shareholders’ equityAVTX overview →